Tyra Biosciences, Inc.
TYRANasdaq
$32.13
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↑ +194.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.0B
Enterprise Value
$1.9B
P/E
—
P/S
—
P/B
5.1
EV/EBITDA
—
PEG
—
FCF Yield
-5.2%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$131.1M
Free Cash Flow (TTM)
-$102.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-33.8%
ROIC
-37.3%
Debt / Equity
—
Net Cash
$85.0M
Return 1Y
+195.9%
Company profile
Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
- CEO
- Todd J. Harris
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- California
- Website
- tyra.bio
Earnings
TYRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.64↑ +36.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.3M | -$26.3M | -$58.9M | -$79.9M | -$104.2M | -$132.8M |
| Net income | -$9.3M | -$26.3M | -$55.3M | -$69.1M | -$86.5M | -$119.9M |
| Diluted EPS | — | -$1.91 | -$1.32 | -$1.62 | -$1.51 | -$2.01 |
| Operating cash flow | -$7.8M | -$23.7M | -$50.3M | -$50.1M | -$69.8M | -$95.1M |
| Free cash flow | -$8.1M | -$24.4M | -$50.8M | -$50.9M | -$70.4M | -$95.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.5M | -$28.6M | -$29.7M | -$31.9M | -$31.5M | -$32.9M | -$36.5M | -$42.0M |
| Net income | -$18.7M | -$24.0M | -$25.6M | -$28.1M | -$28.1M | -$29.9M | -$33.8M | -$39.3M |
| Diluted EPS | -$0.32 | -$0.41 | -$0.43 | -$0.47 | -$0.47 | -$0.50 | -$0.57 | -$0.64 |
| Operating cash flow | -$10.3M | -$17.9M | -$19.6M | -$25.5M | -$23.7M | -$22.4M | -$23.6M | -$32.6M |
| Free cash flow | -$10.7M | -$17.9M | -$19.6M | -$25.5M | -$23.7M | -$22.4M | -$23.7M | -$32.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.